EXACT Therapeutics announces grant of key patent in Japan
Oslo, Norway, 7 May, 2025 - EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, has been informed that the Intellectual Property Office in Japan has granted EXACT its patent no. 7662207 entitled “Treatment of pancreatic cancer”.
The granted patent covers the treatment of pancreatic cancer using EXACT’s proprietary Acoustic Cluster Therapy (ACT®).
Per Walday, CEO of EXACT Therapeutics, comments, ”We are delighted to announce the granting of this key patent in Japan, giving us patent protection within pancreatic cancer until 2040. As one of the major markets outside U.S. and Europe, Japan represents a significant part of the attractive commercial opportunity for the ACT® technology. EXACT has initiated its Phase 2 ENACT trial in pancreatic cancer and remains on track to commence recruitment in the near term.”
About Exact Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT has an on-going Phase 2 trial for the treatment of locally advanced pancreatic cancer. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX).
www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com